Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826605 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5544524 | 0.75 | MAOB (0.47) | ALDH1A1MAOBSMN1; SMN2MAOAMEN1 | |
| SCHEMBL22537024 | 0.75 | KDM4E (0.49) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5544657 | 0.75 | SMN1; SMN2 (0.49) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL1616485 | 0.75 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL2976632 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAOBKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL2608431 | 0.73 | NPFFR1 (0.49) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL23641115 | 0.72 | SLC9A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL10028056 | 0.72 | ALDH1A1 (0.60) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4798053 | 0.72 | ALDH1A1 (0.46) | ALDH1A1MAOBKDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0652869-B1 | IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY | LUSO FARMACO INST (IT) | 1997-03-26 | — | — | EP | disclosed |
| US-5538987-A | Imidazole ethers having a II antagonist activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-07-23 | — | — | US | disclosed |
| EP-0652869-A1 | IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY. | LUSO FARMACO INST (IT) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002467-A1 | IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY | INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885MAOB 2140/4885KDM4E 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.